{"protocolSection":{"identificationModule":{"nctId":"NCT01376011","orgStudyIdInfo":{"id":"1 K23AG030967-01A1-2"},"secondaryIdInfos":[{"id":"1K23AG030967-01A1","type":"NIH","link":"https://reporter.nih.gov/quickSearch/1K23AG030967-01A1"}],"organization":{"fullName":"Brigham and Women's Hospital","class":"OTHER"},"briefTitle":"Modulation of Cerebral Blood Flow Using Quercetin, a Nutritional Supplement","officialTitle":"Hypoxia-inducible Transcription Factor 1 (HIF-1) in Vascular Aging","acronym":"Quercetin"},"statusModule":{"statusVerifiedDate":"2015-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-06"},"primaryCompletionDateStruct":{"date":"2012-06","type":"ACTUAL"},"completionDateStruct":{"date":"2014-12","type":"ACTUAL"},"studyFirstSubmitDate":"2011-06-16","studyFirstSubmitQcDate":"2011-06-17","studyFirstPostDateStruct":{"date":"2011-06-20","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-01-26","lastUpdatePostDateStruct":{"date":"2015-01-28","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Farzaneh Sorond","investigatorTitle":"Principle Investigator","investigatorAffiliation":"Brigham and Women's Hospital"},"leadSponsor":{"name":"Brigham and Women's Hospital","class":"OTHER"},"collaborators":[{"name":"National Institute on Aging (NIA)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to find out if quercetin can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain."},"conditionsModule":{"conditions":["Stroke","Problem of Aging"],"keywords":["quercetin","brain blood flow","aging","memory"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":106,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"healthy young","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: quercetin/placebo"]},{"label":"healthy old","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: quercetin/placebo"]}],"interventions":[{"type":"DIETARY_SUPPLEMENT","name":"quercetin/placebo","description":"Quercetin 500mg once per day versus placebo","armGroupLabels":["healthy old","healthy young"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Define change from baseline levels of HIF-1 concentration and 3 of its regulated proteins after 6 months of quercetin (versus placebo) dietary intake.","description":"Baseline and 6 month blood samples will be analyzed for levels of HIF-1, VEGF, EPO, and NOS","timeFrame":"6 months"},{"measure":"Determine change from baseline brain blood flow after 6 months of quercetin (versus placebo) dietary intake.","description":"Determine cerebral vasomotor reactivity response to 6 months of quercetin intake by measuring changes in middle cerebral artery (MCA) blood flow velocity in response to changes in end-tidal CO2, and assess neurovascular coupling by measuring changes in MCA flow velocity in response to neuropsychological tasks.","timeFrame":"6 months"}],"secondaryOutcomes":[{"measure":"Define change from baseline performance in a battery of cognitive tasks after 6 months of quercetin (versus placebo) dietary intake.","description":"Assess effects of 6 months of quercetin intake on cognitive function using a cognitive battery designed to asses both memory and executive function.","timeFrame":"6 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* healthy volunteers between the ages of 18-75 years old\n\nExclusion Criteria:\n\n* subjects taking vasoactive medications\n* hypertension or vascular disease\n* asthma\n* smokers\n* pregnant women\n* cancer\n* diabetes mellitus\n* history of seizures\n* history of stroke or head trauma\n* subjects taking digoxin, cyclosporine,felodipine, estradiol, or quinolone antibiotics\n* poor transcranial Doppler insonation windows","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Farzaneh Sorond, mD, PhD","affiliation":"Brigham and Women's Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Brigham and Women's Hospital","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M3875","name":"Hypoxia","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000011794","term":"Quercetin"}],"ancestors":[{"id":"D000000975","term":"Antioxidants"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M14334","name":"Quercetin","asFound":"Cathode","relevance":"HIGH"},{"id":"M3982","name":"Antioxidants","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"T41","name":"Quercetin","asFound":"Cathode","relevance":"HIGH"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Fl","name":"Flavonoid"}]}},"hasResults":false}